Investigating the role of a specific gene in myelofibrosis
The Role of PTPN11 in Myelofibrosis
This study is looking at how a gene called PTPN11 might help us find new treatments for myelofibrosis, a serious blood disorder, by seeing how blocking this gene affects blood cell growth in patients, especially those with a common mutation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10545076 on NIH RePORTER |
What this research studies
This research focuses on myelofibrosis, a severe blood disorder characterized by the buildup of fibrous tissue in the bone marrow. The study aims to explore the role of the PTPN11 gene, which may be a new target for treatment. Researchers will investigate how inhibiting PTPN11 affects the growth of blood cells in patients with myelofibrosis, particularly those with a common mutation known as JAK2V617F. By using advanced genetic techniques, the team hopes to identify new therapeutic strategies that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myelofibrosis, particularly those with the JAK2V617F mutation.
Not a fit: Patients with myelofibrosis who do not have the JAK2V617F mutation or other related mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target myelofibrosis and improve survival rates for patients.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other blood disorders, suggesting potential for success in this approach.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Mohi, Golam — University of Virginia
- Study coordinator: Mohi, Golam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.